Rising potentials of epigallocatechin gallate (EGCG) loaded lipid-based delivery platforms for breast cancer

Abstract

AbstractBreast cancer is a major global health concern that requires the development of innovative treatment strategies. Epigallocatechin gallate (EGCG), a polyphenolic phytocompound found abundantly in green tea, has exhibited potential anti-cancer properties, including anti-inflammatory, anti-oxidant, anti-angiogenic, and anti-proliferative effects. However, the clinical translation of EGCG is hindered by its poor bioavailability and stability. Lipid-based nanocarriers have materialized as an optimistic platform for encapsulating various therapeutics due to their high drug-loading capacity, stability, biocompatibility, and versatility. The rationale for encapsulating EGCG-loaded lipid nanoparticles is to enhance the therapeutic efficacy, bioavailability, and targeted delivery of EGCG for breast cancer treatment. This targeted delivery minimizes off-target effects and enhances the accumulation of EGCG within tumors or diseased tissues in a controlled or sustained manner, reducing systemic toxicity. In addition, co-delivery of EGCG with synergistic agents can enhance therapeutic efficacy through complementary mechanisms of action, overcome biological barriers, and can be combined with other treatment modalities, i.e., radiation therapy, immunotherapy, chemotherapy, etc., to achieve synergistic effectiveness and overcome resistance mechanisms. The advancement of EGCG-loaded lipid nanoparticles exhibits the potential effectiveness of EGCG-based treatments, can overcome the challenges of administering EGCG, and can transform cancer therapy and other biomedical applications. Graphical abstract Understanding the potential role of Epigallocatechin gallate (EGCG) in breast cancer treatment through various signaling pathways and further loaded into the lipid-based delivery system for the improvement of mechanical and biological characteristics of the EGCG.